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Background: Patient adherence is an important component of the treatment of chronic disease. 
An understanding of patient adherence and its modulating factors is necessary to correctly 
interpret treatment efficacy and barriers to therapeutic success.
Purpose: This meta-analysis aims to systematically review published randomized controlled 
trials of reminder interventions to assist patient adherence to prescribed medications.
Methods: A Medline search was performed for randomized controlled trials published between 
1968 and June 2011, which studied the effect of reminder-based interventions on adherence to 
self-administered daily medications.
Results: Eleven published randomized controlled trials were found between 1999 and 2009 
which measured adherence to a daily medication in a group receiving reminder interventions 
compared to controls receiving no reminders. Medication adherence was measured as the number 
of doses taken compared to the number prescribed within a set period of time.   Meta-analysis 
showed a statistically significant increase in adherence in groups receiving a reminder inter-
vention compared to controls (66.61% versus 54.71%, 95% CI for mean: 0.8% to 22.4%). 
Self-reported and electronically monitored adherence rates did not significantly differ (68.04% 
versus 63.67%, P = 1.0). Eight of eleven studies showed a statistically significant increase in 
adherence for at least one of the reminder group arms compared to the control groups receiving 
no reminder intervention.
Limitations: The data are limited by imperfect measures of adherence due to variability in data 
collection methods. It is also likely that concomitant educational efforts in the study popula-
tions, such as instructions regarding proper administration and importance of correct dosing 
schedules, contributed to improved patient adherence, both in reminder and control arms. The 
search strategy could have missed relevant studies which were categorized by disease rather 
than adherence.
Conclusions: Reminder-based interventions may improve adherence to daily medications. 
However, the interventions used in these studies, which included reminder phone calls, text 
messages, pagers, interactive voice response systems, videotelephone calls, and programmed 
electronic audiovisual reminder devices, are impractical for widespread implementation, and 
their efficacy may be optimized when combined with alternative adherence-modifying   strategies. 
More practical reminder-based interventions should be assessed to determine their value in 
improving patient adherence and treatment outcomes.
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Introduction
Patient adherence has gained increased recognition for its essential role in treatment 
efficacy. Failure to follow the recommendations of healthcare providers limits the 
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achievement of therapeutic goals.1 Since the first patient 
adherence studies in 1968,2,3 numerous attempts have been 
made to understand, predict, and ultimately enhance patient 
adherence to medical recommendations.4,5 Inadequate 
adherence contributes to morbidity and mortality and raises 
healthcare expenditure,6–9 although the nature of this relation-
ship may be more complex than originally thought.10 This 
is a significant and widespread issue in a population that 
is increasingly reliant on complex pharmacologic therapy. 
Up to 30%–50% of patients are expected to demonstrate 
poor adherence to medication use, regardless of disease 
process, prognosis, or background.7,9,11–13 With a significant 
number of patients relying upon pharmacologic treatment of 
chronic health conditions, failure to adhere to optimal treat-
ment regimens may adversely affect both patient outcomes 
and healthcare costs.
Adherence is a relatively recent term that has replaced the 
notion of compliance when describing patient medication-
taking behaviors.14,15 Compliance is defined as the degree to 
which actual patient drug administration corresponds to the 
prescribed treatment regimen;16 integral to this   definition is the 
assumption that medical advice confers benefit to the patient, 
or that rational behavior dictates necessitate obedience to 
medical advice.17 A broader definition also encompasses the 
extent to which behaviors such as lifestyle modifications or 
diets concur with medical advice.18   Compliance may also 
be measured by outcome-oriented definitions, in which the 
number of prescribed doses taken may determine whether 
a therapeutic result is achieved.19 Yet the term is associated 
with complaisance; the compliant patient submits to their 
doctor’s directives, while the noncompliant patient appears 
disobedient. The passive connotations that the term compli-
ance assigns to the patients’ role in the healthcare process 
has led to a decline in its use.
Adherence has gained popularity as an alternative 
descriptor because it implies a more reciprocal dynamic in 
the   doctor-patient relationship and recognizes salient influ-
ences on medication-taking behavior.14,15,20   However, multiple 
studies assessed in this analysis use the term compliance 
to describe medication-taking behaviors amongst study 
  participants. Because of its prevalence in the   literature, com-
pliance was incorporated into this analysis. Yet the distinction 
between compliance and adherence is important; patient 
motivations must be taken into account to fully explain pat-
terns of medication usage. The determinants of adherence 
are complex. Studies of adherence modifiers, such as those 
analyzing reminder systems, focus on the multifaceted 
motivations behind medication-taking behavior. Barriers to 
  adherence vary widely, and include concerns about efficacy, 
fear of side effects, inconvenience, a poor doctor-patient 
relationship, lack of social support, patient motivation, 
or incorrect education regarding proper use.21,22 Research 
regarding the theoretical groundwork of adherence, impedi-
ments, facilitators, and interventions serve to highlight its 
complexity and the practical difficulties of improving adher-
ence in a patient population.23–28 Over 200 variables influenc-
ing compliance, such as socioeconomic factors and disease 
pathology, have been studied since 1975, yet none have 
demonstrated a consistent link with adherence rates.8,9,29–32 
Furthermore, studies of adherence vary significantly in 
methodology, patient population, disease processes, treatment 
regimens, and definition of adherence. The variation in study 
context and measurement is likely to account for significant 
disparities of observed adherence outcomes. Measures of 
adherence vary between studies; some use outcome oriented 
measures, others use a predetermined percent of doses taken 
to categorize patients as adherent or non-adherent, while 
some measure adherence more fluidly, reporting the overall 
percentage of total doses taken.
Patient adherence has substantial implications in pre-
ventative medicine and the treatment of chronic disease. It 
is a key component of successful medical management; an 
understanding of patient adherence and its modulating   factors 
is crucial to interpreting treatment efficacy and barriers to 
therapeutic success.33 Non-adherence increases financial 
burdens on healthcare systems and leads to unnecessary 
pharmacologic and diagnostic interventions.7–9,16   Adherence 
is the fundamental link between intent and outcome of 
  medical care.16
Interventions aimed at improving adherence attempt to 
maximize successful healthcare delivery. There are various 
stages of the healthcare process that provide potential for poor 
adherence.5 These include failure to seek early or preventative 
care, attend follow-up appointments, fill prescriptions, follow 
physician instructions,34 use correct doses or timing, continue 
treatment for the full duration, or refill prescriptions.8 In many 
instances, non-adherence is unintentional, but patient beliefs 
may also contribute to intentional deviation from prescribed 
treatment plans. Ultimately, however, patient decisions 
regarding treatments are likely to reflect their own beliefs and 
personal circumstances. In addition to encouraging patient 
adherence to prescribed medications, healthcare providers 
should attempt to contribute to the patient’s decision-making 
process.9 Three categories of adherence-enhancing strategies 
have been defined: enabling, consequence, and stimulant.35 
Enabling strategies arm patients with the tools necessary 
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for adherence, and include patient education, simplified 
medication regimens, cost-effective therapies, and access to 
medical care and prescriptions. Consequence strategies aim 
to reinforce adherence by providing incentives for accept-
able adherence. Stimulant strategies are aimed at prompt-
ing dose-taking. Examples include electronic reminders, 
environmental cues, peer support, and special packaging 
or organizers to encourage correct and timely medication 
usage. Stimulant strategies may have a synergistic effect 
when combined with enabling strategies to enhance adher-
ence to home medication use.36 Methods of measuring 
adherence varied amongst studies. There is no gold standard 
measurement of adherence, and this complicates our ability 
to uniformly quantify adherence.7,37 Both direct and indirect 
measures have been utilized in an attempt to measure medi-
cation usage. Direct measures, such as serum or urine drug 
levels, are more challenging, invasive, expensive, and have 
limited applications. Their use is restricted to hospitalized 
patients receiving single-dose, intermittent therapies.34 These 
methods may likewise discount individual pharmacokinetic 
and metabolic variations.
Indirect measures, which are utilized in the majority of 
patient adherence studies, include patient medication diaries, 
interviews, pill counts, prescription filling dates, electronic 
monitoring devices, and therapeutic or preventative outcome 
measures.34 Electronic monitoring devices, such as MEMS 
(medication event monitoring system), enable measure-
ment of both frequency and timing of medication dosing. 
They have also revealed the phenomenon of “white coat 
adherence,” where medication usage significantly increases 
immediately prior to doctor appointments.38,39 MEMS them-
selves have been postulated to stimulate adherence because 
they provide evidence of true medication usage, and could 
be considered a less obtrusive reminder device than phone 
calls or text messages.39
The extent of the relationship between treatment adher-
ence and treatment outcomes has yet to be fully elucidated. 
Understanding the connection between adherence and 
certain moderating factors, such as patient beliefs, disease 
features, or therapeutic regimens, is essential to identifying 
determinants of treatment outcomes and designing methods 
to improve patient adherence. Interventions have included 
the use of reminder mechanisms to maximize medication 
  adherence. In this study we examined the effect of remind-
ers on patient medication adherence using meta-analysis 
to integrate research findings with statistical analysis of 
multiple studies. Reminders are one extensively-studied 
adherence-enhancing strategy. Such reports have provided 
conflicting evidence for the efficacy of reminder systems in 
improving adherence to medication usage. The success of 
reminders is likely to be heavily dependent on other com-
plex determinants of medication usage, such as medication 
type, patient population, or disease process. We attempt to 
quantify the correlation between reminder interventions and 
quantity of adherence, or number of doses taken over a period 
of time, in order to better assess the overall significance of 
this intervention
The reminder systems in this review target “treatment” or 
“secondary” non-adherence, which is the failure to correctly 
utilize prescribed treatment plans.8,34 Patient non-adherence 
may be intentional, in which the patient purposefully declines 
to take a medication for reasons that appear rational when 
subject to analyses; such reasons may include incorrect diag-
nosis or prescription, development of side effects or adverse 
reactions, or awareness of a change in one’s disease process.40 
Reminder systems largely target unintentional non-adherence 
but may also diminish intentional non-adherence by provid-
ing patients with feedback while appealing to a desire to 
appear adherent when use is scrutinized by an outside party. 
The use of patient reminders has been extensively studied as 
one method of improving adherence to behavioral, lifestyle, 
and pharmacologic treatment regimens. Reminders provide 
recurrent cues, encouragement, or motivation for patients to 
adhere to medical recommendations, but it is unclear whether 
their function differs in daily medication usage versus life-
style modifications or preventative healthcare. Our analysis 
specifically assesses the use of reminders in influencing 
adherence to daily medication use.
Methods
A Medline search was conducted for journal articles pub-
lished from 1968 through to June 2011. The search was 
limited to English-language randomized controlled trials 
which contained the keywords “adherence” or “  compliance” 
and “reminder”. This yielded 243 results. Studies of health-
care provider adherence, case reports, and studies analyzing 
patient adherence to office visits, refills, vaccinations, screen-
ing tests, lab work, or exercise, or behavioral modifications 
were excluded. Included were studies which examined adher-
ence to prescribed medications or substances that have to be 
utilized at least once daily. This was done so that analysis 
would more closely reflect medication adherence rather 
than adherence to lifestyle interventions. We then selected 
for trials that met the following criteria: utilized a reminder-
based intervention, measured adherence as a primary end-
point, and measured quantity of adherence (measured as 
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[number of bottle openings or doses taken]/[ doses prescribed 
during that time] × 100) rather than the percentage of the 
sample meeting a certain definition of adherence. This unit 
of measurement was selected so that comparison between all 
control and reminder groups could be performed.
Data analysis
Medication adherence was measured as the number of 
doses taken compared to the number prescribed within a 
set period of time. Some trials reported adherence over the 
entire study period while some only gave the adherence rate 
at baseline and endpoint for each group. We averaged these 
numbers to produce comparable data to trials that reported 
it over the entire study period. There was no predefined per-
centage of dose-taking used to define “adherence” versus 
“non-  adherence.” Adherence between reminder and control 
groups was compared using paired t-tests. Average adherence 
between different medication types and monitoring methods 
was compared using Kruskal–Wallis tests. All statistical 
analysis was performed using SAS (v9.1; SAS Institute, 
Cary, NC).
Results
Eleven trials were analyzed.41–51 All studies contained a con-
trol group which did not receive any reminder intervention. 
Sample sizes ranged from 22 to 398. Medications included 
highly active antiretroviral therapy (HAART), inhaled 
corticosteroids or long-acting beta-agonists, adapalene gel, 
Vitamin C, daily sunscreen, prostaglandin eye drops, and 
angiotensin-converting enzyme (ACE) inhibitors, calcium 
channel blockers, or beta-blockers (Table 1). Six studies 
used electronic tracking devices to monitor medication use, 
four relied upon self-reported compliance, and one used 
the dose count on an inhaler. Three trials had a phone text 
message reminder intervention arm, one used regular phone 
call reminders, one used an interactive voice response phone 
reminder device, one used video-telephone call reminders, 
two used pager text reminders, two used programmed elec-
tronic audiovisual reminder devices, and one used parental 
reminders or frequent office visits (Table 1). For those that 
reported both electronic- and patient-reported adherence 
rates, we analyzed electronically monitored adherence rates 
only. Some combined reminder systems with education and 
development of adherence strategies.
Eight of eleven studies showed a statistically significant 
increase in adherence for at least one of the reminder group 
arms compared to the control group. Reminder groups 
averaged 11.9% higher adherence than the corresponding 
control groups (95% CI for mean: 0.8% to 22.4%). Using a 
paired t-test, reminder groups had higher adherence than the 
corresponding control groups (P = 0.04). Adherence aver-
aged 66.61% in the groups receiving reminders, compared 
to 54.71% in control groups. The range of adherence was 
36%–88.45% in the reminder groups and 18.6%–86.75% in 
the control groups.
No significant difference in adherence rates was seen 
for patient reported results compared to electronic moni-
toring systems. Among trials using participant-reported 
results or pill counts to calculate adherence rates, overall 
adherence was 62.15%, compared to 60.86% among trials 
using electronic monitoring devices (P = 0.72). The aver-
age reminder group adherence rate was 68.04% among 
trials using self-reported adherence and 63.67% for those 
relying upon electronic monitoring (P = 1.0). In control 
groups, adherence was 56.25% for self-reporting or pill 
count groups versus 53.43% for electronically monitored 
groups (P = 0.86).
Trials utilizing phone or pager text message reminder 
interventions had an average adherence rate of 51.31% in 
reminder groups. There was no statistically significant dif-
ference compared to participants receiving traditional phone 
calls, video-telephone calls, or interactive voice response 
system reminders (67.65% average adherence, P = 0.14). The 
two trials using electronic monitoring systems with integrated 
audio or audiovisual reminder devices resulted in 84.23% 
average adherence, although neither showed a statistically 
significant increase in adherence over control groups.
The average adherence rate among those receiving 
HAART therapy was 54.58% in control groups and 62.58% in 
intervention groups, with one of three trials showing a statisti-
cally significant improvement in adherence.   Adherence rates 
for those receiving asthma inhaler treatments was 63.13% 
among controls and 72.1% for reminder groups, with both 
trials showing a significant improvement over controls. For 
those receiving blood pressure medications, adherence was 
77.88% without intervention and 81.73% with   reminders; one 
of the two trials showed a statistically significant improve-
ment in adherence (P = 0.03). Among those receiving non-
prescription medications (daily vitamin C or sunscreen), 
adherence among control groups was 24.3% versus 60.2% 
among reminder groups; both demonstrated a statistically sig-
nificant improvement (P = 0.001, 0.001). For those receiving 
prostaglandin eye drops, adherence was 48.5% and 67.75% 
among control and reminder groups, respectively, while for 
adapalene gel, adherence was 59% in the control group and 
55.33% for all reminder interventions.
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Discussion
Dose adherence was significantly increased by reminder-
based interventions (65.94% in the reminder groups versus 
54.71% in the control groups, P = 0.04), showing that it is 
possible to modify medication adherence rates. It is unclear 
whether this effect is attributable to the reminders’ function 
as a memory aid or whether the knowledge that their adher-
ence was being monitored prompted participants to utilize 
medications to a greater extent.
The literature analyzed in this analysis relied upon 
indirect measures of patient adherence (Table 1). Each of 
these methods is vulnerable to certain flaws in reliability. 
Outcome measures may not be directly attributable to 
medication usage. Self-reporting and pill counts are likely to 
overestimate adherence, and patient interviews have varying 
sensitivity among different patient subgroups.52 All stud-
ies in this analysis used indirect measures of adherence.34 
There was no significant difference in self-reported and 
electronically-recorded adherence rates. Of the five trials in 
this analysis using patient-reported results or dose counts to 
quantify adherence, three displayed a statistically significant 
increase in adherence with reminder interventions (P = 0.001, 
P = 0.03). Despite the opportunity for study participants to 
provide inflated adherence rates when self-reporting medica-
tion usage, adherence rates in self-reporting and pill count 
intervention groups were comparable to those monitored via 
electronic tracking devices (68.04% versus 63.67%, P = 1.0). 
Electronically measured medication usage is thought to be 
a more reliable assessment of adherence; the fact that these 
rates were comparable to self-reported rates implies that 
reminders were equally successful in both groups, or that 
monitoring increased participants’ awareness of medication 
usage and exerted a direct positive effect on adherence rates. 
Five of the six trials utilizing MEMS caps or other electronic 
monitoring devices showed a statistically significant increase 
in adherence in at least one intervention arm. This suggests 
that monitoring devices themselves may act to increase 
adherence independently of other interventions, or may act 
as a reminder by increasing awareness of medication usage 
monitoring.
It is unclear whether one type of reminder system has 
a more significant impact on adherence. When comparing 
text and voice-based interventions, those receiving phone 
or pager texts had an absolute average adherence rate of 
51.31%28,30,31,34,35 compared to 67.65% among those receiv-
ing traditional phone calls, video-telephone calls, or calls 
from automated interactive voice response systems.33,36,38 
Four out of five text message interventions demonstrated 
a statistically significant improvement in adherence, as did 
four of the five voice-based interventions. The two electronic 
monitoring devices that had integrated reminder alarms29,37 
both had high absolute rates of adherence (88.45% and 80%), 
yet failed to generate a statistically significant improvement 
over controls.
Another aspect of reminder systems that may influence 
adherence rates is the message behind the reminder, or put 
another way, what is being communicated to the patient. The 
more a person is intrinsically motivated towards a certain 
task the more likely it is the person will engage and persist 
in the task.53,54 Physicians may increase positive health out-
comes, including adherence, if they interact in an “autonomy 
supportive” rather than “controlling” manner when treating 
patients and their families.55 It could be that reminder systems 
that target a patient’s self-reported reasons for adherence are 
more effective than neutral statements or warnings that seem 
more externalized for the patient.
The type of medication may also influence observed 
adherence rates, yet it is difficult to discern a pattern from 
our limited analysis. Chronic and asymptomatic illnesses may 
be most resistant to adherence-enhancing strategies.1 Yet in 
this analysis, those receiving blood pressure medications had 
the highest average rates of adherence in both control and 
reminder groups (77.88% and 81.73%) followed by those 
receiving asthma therapy (63.13% versus 72.1%). Among 
three trials in which participants received HAART therapy, 
only one of three showed a statistically significant improve-
ment in adherence with reminders, and average adherence 
among non-reminder groups was only 54.58%, compared to 
62.58% among those receiving the reminder intervention.
Cost-effectiveness and long-term practicality of the 
reminder systems used in these studies are likely to inhibit 
their widespread implementation. Repeated phone calls, text 
messages, beeper systems, or frequent follow-up appointments 
for relatively stable conditions require significant financial 
investment and manpower. Repeated reminders may be viewed 
as intrusive rather than helpful. More practical reminder-based 
interventions include blister-packs to measure dose usage, 
calendars, dose counters, and other special containers that 
enhance awareness of dose-usage. Evidence also suggests 
that combination interventions confer greater efficacy than 
single-method approaches. Combining adherence-modifying 
strategies like reminders with other interventions produces a 
greater overall effect than any intervention alone.56–58 Further 
interventions may entail adapting treatment plans to patient 
preferences, simplifying treatment regimens, enlisting   family 
support, providing education regarding side effects and 
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Table 1 Randomized controlled trials measuring percent adherence in reminder and control groups
Study Control n 
(total)
Adherence 
(control group; %)
Reminder Reminder description n 
(total)
Adherence 
(test group; %)
P-value monitoring
Armstrong48 No reminder 35 30.00 Phone text  
reminder
A daily text message containing the day’s weather  
and a reminder to apply sunscreen (“Tues. Sunny.  
High 71, Low 61. Slap on some sunscreen today.”)
35 56.10 Sunscreen 0.001 Electronic monitoring device
Standbygaard44 No reminder 12 77.15 Phone text  
reminder
Daily short message service (SMS) text reminder at 
10 am for 8 weeks telling participants to take their 
asthma medication
10 79.70 Discos Seretide (inhaled corticosteroid  
and long-acting beta-agonist)
0.019 Dose count on inhaler disc
Okeke49 No reminder 31 48.50 Phone call  
reminder
Reminder telephone calls from the coordinator  
once per week for one month then every other  
week, which included administration of a questionnaire  
about drop-taking behavior, difficulty with drops side  
effects, and opportunities for participant questions
35 67.75 Prostaglandin eye drops 0.01 Dosing Aid recording device
Christensen50 No reminder 179 86.75 Programmed  
electronic  
audiovisual  
reminder
The device is operated with tablet blister cards and 
was customized to fit the blister cards of the study 
medication. The device gives the patient an audiovisual 
reminder when it is time to take the medication
219 88.45 Telmisartan 0.072 Self reported compliance
Cococila47  No reminder 48 18.60 Phone text  
reminder
3 types of daily message were sent. Basic message 
ending in a question mark (“Hi, its Tim: any vitamin C  
2 day?”); reinforcing message to those who replied  
as expected including encouraging statements with  
brief jokes and ending with a smiley (“Tim here again: 
Ur doing super! Tip: 2 steal ideas from one person is 
plagiarism; 2 steal from many is research!:)”);  
and correcting message to those who did not  
acknowledge the basic reminders (with non-amusing  
feedback with the importance of taking the vitamin  
(“Again Tim: do your best to take the vitamins: they  
help fight cold and flu!”)
51 64.30 vitamin C 0.001 Self reported compliance
Fulmer51 No reminder 18 69.00 Phone call  
reminder
15 75.00 Ace-inhibitors, calcium channel-blockers 
(CCB), beta-blockers
,0.05 Medication event monitoring 
system (MEMS) caps
videotelephone  
call reminder
A daily videotelephone telephone call lasting  
3–5 minutes consisting of a brief greeting and a  
question asking whether participants had traken  
their medications the previous day
17 83.00 ,0.05
Safren41 Medications  
monitoring  
only
19 55.00 Pager text  
reminder
Daily text message included dose reminders 
including drug name, number of pills, and  
specific decriptions (eg: “take 2 Combivir with  
water” or “take the 2 blue pills now”)
25 63.00 HAART 0.03 Self reported compliance
Bender45 No reminder 25 49.10 interactive voice  
response  
system reminder
2 programmed calls separated by one month including 
an explanation of how the call worked, followed by  
3 questions asking whether the participant had 
experienced asthma symptoms in the past week: if 
their anwer was affirmative participants were told 
that controller medications should help prevent these 
symptoms; they were also asked wether they were 
filling and using their medications
25 64.50 Fluticasone/sal merterol (inhaler) 0.0032 Electronic tracking device
Andrade42 Monthly 
adherence  
counseling,  
no reminders
29 65.00 Programmed  
electronic  
voice reminder  
device
Disease Management Assistance System (DMAS), a  
battery powered electronic device that produces a  
timed, programmed voice message prompting subjects   
to take their antiretrovitrals
29 80.00 Highly active antiretroviral therapy 
(HAART)
0.25 Electronic drug exposure 
monitor (eDEM) caps
Simoni43 No  
intervention
57 43.75 Pager text  
reminder
A minimum of 3 daily text messages included dose  
reminders, educational messages about the disease and   
treatment, entertainment and adherence assesments
56 44.75 HAART .0.5 Self reported compliance
Yentzer46 No reminder 12 59.00 Phone call reminder 8 48.00 adapalene .0.5 MEMS cap
Parental reminder 14 36.00 .0.5
Frequent office visits 12 82.00 ,0.5
Average adherence 54.71 66.61
Standard deviation 19.91 15.93
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device
Disease Management Assistance System (DMAS), a  
battery powered electronic device that produces a  
timed, programmed voice message prompting subjects   
to take their antiretrovitrals
29 80.00 Highly active antiretroviral therapy 
(HAART)
0.25 Electronic drug exposure 
monitor (eDEM) caps
Simoni43 No  
intervention
57 43.75 Pager text  
reminder
A minimum of 3 daily text messages included dose  
reminders, educational messages about the disease and   
treatment, entertainment and adherence assesments
56 44.75 HAART .0.5 Self reported compliance
Yentzer46 No reminder 12 59.00 Phone call reminder 8 48.00 adapalene .0.5 MEMS cap
Parental reminder 14 36.00 .0.5
Frequent office visits 12 82.00 ,0.5
Average adherence 54.71 66.61
Standard deviation 19.91 15.93
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expected outcomes, monitoring adherence, and providing 
patient feedback. When attempting to improve adherence, 
interventions should aim to improve patient understanding, 
recall, and motivation.59 Reminders potentially target each 
of these factors and supplement additional patient educa-
tion strategies. They may be best utilized in populations for 
whom forgetfulness is a major cause of unintentional non-
adherence.
The studies used in this analysis have several limitations. 
The data are limited by imperfect measures of adherence 
due to variability in data collection methods. In many 
of these trials, patients were aware that they were being 
monitored and this could be expected to influence adher-
ence. Studies may be limited by their inability to determine 
whether reminder intervention improved dose-taking 
behavior or simply increased use of medication monitors or 
disposal of pills. This analysis does not correlate adherence 
rates with treatment and disease outcomes, so the overall 
effect of the observed changes in adherence cannot be 
determined. The necessary duration of reminder systems 
for optimal improvement in adherence was not determined 
but likely contributed to variations seen in reminder 
efficacy. It is likely that concomitant educational efforts 
in the study populations, such as instructions regarding 
proper administration and importance of correct dosing 
schedules, contributed to improved patient adherence, both 
in reminder and control arms. Approaches used in these 
studies were simple compared to most chronic disease 
regimens. Further research is needed to identify those 
reminder mechanisms which have the greatest effect on 
maximizing adherence and to study multifaceted versus 
single-intervention approaches. The search strategy could 
have missed relevant studies which were categorized by 
disease rather than adherence. Studies yielding significant 
results are more likely to have reached publication, and 
studies may only be conducted on conditions in which 
problematic adherence rates were expected.
It appears that patient medication use may be improved by 
reminder-based interventions. Strategies directed at improv-
ing medication-taking behavior should target the underlying 
barriers to adherence. Reminders may therefore provide a 
useful adjunct to adherence-enhancing strategies, particularly 
in populations for whom recurrent cues are helpful in assuring 
correct medication usage.
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